Semax vs NA-Semax-Amidate
Comparing original Semax with its N-acetyl amidated derivative NA-Semax-Amidate for stability and bioavailability.
Last updated: February 1, 2026
Semax
N-Acetyl Semax Amidate
Overview
Semax and NA-Semax-Amidate are closely related peptides - NA-Semax-Amidate is a modified form of Semax with N-acetylation and C-terminal amidation. These modifications are intended to enhance stability and potentially bioavailability. Neither is FDA-approved; Semax is approved in Russia.
Key Facts
| Aspect | Semax | NA-Semax-Amidate |
|---|---|---|
| Base Structure | ACTH 4-10 + Pro-Gly-Pro | Same core |
| N-terminus | Free | Acetylated |
| C-terminus | Free carboxyl | Amidated |
| Amino Acids | 7 | 7 |
| Approval Status | Russia | Nowhere |
Structural Modifications
N-Acetylation (NA-)
| Aspect | Effect |
|---|---|
| Chemical Change | Acetyl group added to N-terminus |
| Purpose | Protect from aminopeptidases |
| Result | Reduced enzymatic degradation |
| Impact | Potentially longer half-life |
C-Terminal Amidation (-Amidate)
| Aspect | Effect |
|---|---|
| Chemical Change | Carboxyl converted to amide |
| Purpose | Protect from carboxypeptidases |
| Result | Reduced enzymatic degradation |
| Impact | Potentially longer half-life |
Why These Modifications?
Peptides face rapid degradation:
- Aminopeptidases attack N-terminus
- Carboxypeptidases attack C-terminus
- Modifications block these attack sites
- Result: potentially improved stability
Evidence Comparison
| Aspect | Semax | NA-Semax-Amidate |
|---|---|---|
| Human Trials | Some (Russia) | None |
| Regulatory Review | Russian approval | None |
| Research Publications | Multiple | Very few |
| Mechanism Studies | Available | Limited |
Critical Evidence Gap
Semax: Has some clinical background and Russian approval
NA-Semax-Amidate: Modifications are theoretically sound but:
- No direct comparative studies
- limited human data (8 sources) of the modified form
- Assumes modifications improve without changing activity
- Actual bioavailability data lacking
Proposed Benefits of Modifications
| Claim | Evidence |
|---|---|
| Improved stability | Theoretical (common modification) |
| Better bioavailability | Not directly tested |
| Longer duration | Not directly tested |
| Enhanced CNS penetration | Speculative |
| Same mechanism | Assumed, not verified |
Administration
| Aspect | Semax | NA-Semax-Amidate |
|---|---|---|
| Route | Intranasal | Intranasal |
| Half-life | Short (minutes) | Unknown |
Safety Considerations
| Factor | Semax | NA-Semax-Amidate |
|---|---|---|
| Human Safety Data | Russian post-market | None |
| Long-term Use | Some data (Russia) | Unknown |
| Modifications Safety | N/A | Not specifically tested |
| Quality Control | Russian pharma (in Russia) | None |
Unknown Factors for Modified Form
- Do modifications affect receptor binding?
- Do modifications change side effect profile?
- What is actual bioavailability improvement?
- Are there new metabolites with unknown effects?
Regulatory Status
| Aspect | Semax | NA-Semax-Amidate |
|---|---|---|
| Russia | Approved | Not approved |
| US/EU | Not approved | Not approved |
| Quality Sources | Russian pharmacies | Research chemical only |
| WADA Status | Not specifically listed | Not specifically listed |
Quality and Availability
| Factor | Semax | NA-Semax-Amidate |
|---|---|---|
| Pharmaceutical Grade | Yes (Russia) | No |
| Research Chemical | Also available | Only option |
| Quality Consistency | Variable (source) | Unknown |
| Purity Verification | Possible (legit sources) | Difficult |
Key Differences
| Factor | Semax | NA-Semax-Amidate |
|---|---|---|
| Modifications | None | N-acetyl + C-amide |
| Evidence Base | Low-moderate | Very low |
| Regulatory Status | Approved (Russia) | Nowhere |
| Stability | Standard | Theoretically improved |
| Research | More extensive | Minimal |
Theoretical vs Actual
| Claim | Theoretical | Actually Demonstrated |
|---|---|---|
| Improved stability | Yes | Not measured for this peptide |
| Better absorption | Possible | No data |
| Same effects | Likely | Not verified |
| Enhanced efficacy | Maybe | No comparison studies |
Summary
- Semax is the original peptide with Russian approval and some clinical evidence
- NA-Semax-Amidate has theoretical stability improvements but no direct evidence
- Modifications are chemically rational but unverified for this specific peptide
- No comparative studies exist
- Neither is FDA/EMA approved
- Semax has pharmaceutical availability in Russia; NA-Semax-Amidate does not
- Research chemical quality is uncertain for both
This comparison is for educational purposes only. Neither compound is approved by the FDA or EMA. NA-Semax-Amidate has no clinical data. Products sold as research chemicals have uncertain quality.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.